Compounded Semaglutide: What a Real Consult Would Tell You

A responsible read on this how-to guide starts with mechanism, side effects, access, and monitoring rather than promises. That frame keeps the discussion useful for patients without pretending the evidence is stronger than it is.

A friend of mine, a registered dietitian in Houston, called me last October after one of her clients showed up to a session with a box of syringes, a vial labeled “semaglutide 5mg/mL,” and absolutely no idea what dose she was supposed to draw. The client had ordered through some telehealth platform, gotten a PDF with a dosing table, and assumed the volume in the syringe was the dose. It wasn’t. The milligram dose was what mattered, and the concentration on that particular vial meant the volumes were tiny. She’d been giving herself roughly triple her intended dose for two weeks and wondering why she couldn’t keep food down.

That story captures, in miniature, everything that matters about compounded semaglutide. The drug itself works. The science is solid. But the patient experience depends almost entirely on the clinical scaffolding around it: who prescribes it, how the pharmacy compounds it, how the titration is managed, and whether anyone actually walks you through the basics before you stick a needle in your abdomen.

This is what a proper briefing looks like.

The Drug and the Two Pathways to Get It

Semaglutide is a GLP-1 receptor agonist. Novo Nordisk developed it. It came to market as Ozempic in 2017 for type 2 diabetes and as Wegovy in 2021 for chronic weight management. Those are the brand-name finished products, FDA-approved, manufactured at industrial scale.

Compounded semaglutide uses the same active pharmaceutical ingredient. A state-licensed or 503A compounding pharmacy prepares it for an individual patient under a clinician’s prescription. It is not FDA-approved as a finished product. That distinction is real and worth understanding, but it doesn’t mean one pathway is inherently dangerous and the other is safe. It means the regulatory framework, the manufacturing oversight, and the evidence trail are structured differently.

Compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (plus parallel state pharmacy regulations) is a well-established part of American pharmacy. It predates GLP-1 therapy by decades. Dermatologists compound topicals. Pediatricians compound liquid formulations for kids who can’t swallow pills. The practice itself isn’t novel; the scale of demand for compounded semaglutide is.

What the Trials Actually Showed

The registrational evidence for semaglutide is built entirely on the brand-name finished products. That’s an important caveat. But the pharmacology of the active ingredient informs what you can reasonably expect from a compounded preparation, even if it hasn’t been studied as a finished product in its own registrational trials.

The headline trial is STEP-1: 1,961 adults with overweight or obesity, no diabetes, randomized to weekly semaglutide 2.4 mg or placebo for 68 weeks alongside a lifestyle intervention. The semaglutide group lost approximately 14.9% of body weight from baseline. Placebo lost 2.4% (Wilding et al., New England Journal of Medicine, 2021). That’s a large effect. But individual responses ranged widely. Some people lost 5%. Some lost 25%.

STEP-3 layered on intensive behavioral therapy and saw a directionally similar, slightly larger effect. STEP-5 extended follow-up to 104 weeks and showed weight reduction was sustained as long as therapy continued. STEP-4, which is the one that should get more attention than it does, took patients who had already responded and randomized them to continue semaglutide or switch to placebo. The placebo-switch group regained significant weight. The implication is fairly blunt: for most people, this is not a 68-week fix. It’s ongoing therapy.

On the diabetes side, the SUSTAIN program established semaglutide’s glycemic and cardiovascular effects at lower doses (0.5 mg and 1.0 mg weekly, later 2.0 mg in SUSTAIN FORTE). The cardiovascular outcome trial, SUSTAIN-6 (Marso SP et al.), showed a reduction in the composite of major adverse cardiovascular events in a high-risk diabetes population.

The boring truth? Semaglutide works well, it’s well-characterized, and its side effects are concentrated early. It is not magic, and it does not replace everything else about how a person eats and moves.

How Dosing Works (and Where Confusion Creeps In)

The titration schedule from the STEP trials, reflected on the Wegovy label, is a five-step escalation:

• 0.25 mg weekly for four weeks
• 0.5 mg weekly for four weeks
• 1.0 mg weekly for four weeks
• 1.7 mg weekly for four weeks
• 2.4 mg weekly as the maintenance dose

Full escalation takes about sixteen to seventeen weeks if every step is held for four weeks. Compounded programs typically follow the same milligram increments.

Here’s where it gets tricky. The concentration of the compounded solution varies by pharmacy. One pharmacy might compound at 2.5 mg/mL. Another at 5 mg/mL. A third at some other concentration. The volume you draw into the syringe changes accordingly, but the milligram dose is what matters clinically. If you switch programs or pharmacies mid-treatment, confirm the milligram dose at each step, not the volume. This single point would have saved my dietitian friend’s client two miserable weeks.

The schedule is flexible. Struggling with nausea at 0.5 mg? Stay there an extra four weeks. Doing well clinically at 1.7 mg? You don’t have to push to 2.4 mg. These are clinical decisions, not checkboxes.

Storage is standard: refrigerate at 36 to 46 degrees Fahrenheit. Limited time at room temperature is fine for transport. Rotate injection sites between abdomen, thigh, and upper arm to reduce local irritation.

The Side-Effect Profile: Mostly GI, Mostly Early

Gastrointestinal symptoms dominate. Nausea, diarrhea, constipation, vomiting, abdominal discomfort. These show up across the STEP and SUSTAIN programs and in every real-world cohort dataset. Most events are mild to moderate, clustered in the first eight to twelve weeks, and resolve with continued therapy or a temporary dose hold.

Less common but clinically important:

• Gallbladder events, especially in patients losing weight rapidly. This isn’t unique to semaglutide; rapid weight loss from any cause increases gallstone risk.
• Acute pancreatitis, rare, but severe abdominal pain radiating to the back with fever warrants immediate evaluation.
• Thyroid C-cell tumors: a signal from rodent studies that has not been replicated in humans. Both Wegovy and Ozempic carry a boxed warning about this and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).

Hypoglycemia on semaglutide alone in a non-diabetic patient is uncommon because the insulin-stimulating effect is glucose-dependent. The risk goes up when semaglutide is combined with insulin or sulfonylureas, and in that case, dose adjustment of the other agent is the intervention.

My honest take: the side-effect profile is manageable for most people, but the first month can be genuinely unpleasant. Programs that breeze past this in their marketing are doing patients a disservice.

What It Costs and Why the Gap Exists

Brand-name Wegovy and Ozempic carry a list price north of $1,300 per month. Cash-pay rates at most retail pharmacies sit in the $1,000 to $1,400 range. Insurance coverage for the weight-management indication is inconsistent; some plans cover it, many don’t, and prior authorization requirements can be labyrinthine.

Compounded programs run substantially less. HealthRX, which operates under LegitScript certification and is available in 44 US states, prices its program at $179.99 to $279.99 per month depending on dose. That’s a real number, not a promotional hook.

The price gap is structural. Brand-name finished products carry the cost of regulatory submissions, global clinical trial programs, post-marketing surveillance, manufacturing at industrial scale, and the commercial margin that funds Novo Nordisk’s next generation of research. Compounded preparations are produced through a different regulatory pathway at a different scale with a different cost structure. Neither pathway is cheating; they’re just different models.

If you plan to use an HSA or FSA, confirm the program’s invoicing format before enrolling. Some plans reimburse easily; others want specific documentation.

The Comparison That Actually Matters

Compounded semaglutide vs. brand-name Wegovy/Ozempic is not a question of “real vs. fake.” It’s the same active ingredient arriving through different supply pathways with different regulatory profiles.

Three practical differences to keep in mind:

1. Evidence base. The STEP and SUSTAIN trial data were generated with the brand-name finished products. That evidence informs expectations for the compounded version but doesn’t directly extend to it.
2. Manufacturing oversight. Brand-name products go through FDA’s finished-product regulatory framework. Compounded preparations are overseen by state boards of pharmacy (503A) or, for 503B outsourcing facilities, by the FDA under a separate framework.
3. Adverse-event surveillance. The pharmacovigilance system is more complete for brand-name products. Adverse events from compounded preparations are less systematically captured.

None of that makes compounded semaglutide unsafe by default. It means you should understand what you’re choosing and why. Patients who want a deeper walkthrough of the clinical and practical questions (dosing, what to eat in the first three months, when to call a clinician) can read this how-to guide, which is structured around the questions that come up in a real intake conversation. It’s background reading, not a replacement for an actual clinical relationship.

When You Should Pick Up the Phone

Self-management has limits. Contact your prescribing clinician or program for:

• Persistent severe abdominal pain, especially with radiation to the back or fever
• Inability to keep down fluids for more than 24 hours, or signs of dehydration
• New right upper quadrant pain after meals, or jaundice (gallbladder territory)
• New or worsening reflux that doesn’t respond to meal-timing adjustments
• Mood changes, including new or worsening depressive symptoms
• Pregnancy, planned pregnancy, or breastfeeding (before the next dose)
• Personal or family history of medullary thyroid carcinoma or MEN2 (this should have been caught at intake; if it wasn’t, raise it immediately)
• Hypoglycemic episodes if you’re also on insulin, sulfonylureas, or other glucose-lowering agents
• Concerns about drug interactions, particularly with warfarin or other narrow-therapeutic-window medications, given that semaglutide slows gastric emptying

Frequently Asked Questions

Is compounded semaglutide the same drug as Ozempic and Wegovy? The active ingredient, semaglutide, is the same. The finished product, the regulatory category, and the manufacturing pathway are different. Brand-name Ozempic and Wegovy are FDA-approved finished products manufactured by Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient under a clinician’s prescription and is not FDA-approved as a finished product.

How long does treatment typically last? STEP-1 captured 68 weeks. STEP-5 extends to 104 weeks. Clinical experience now goes beyond two years. Treatment duration is individualized based on goals, response, and tolerability.

Is the weight loss sustained after stopping? STEP-4 showed significant regain in the group switched to placebo after a lead-in period. For many patients, sustained results depend on continued therapy. Long-term outcomes after discontinuation hinge on the lifestyle changes consolidated during treatment.

Do I need labs to start? A careful program will document baseline labs: metabolic panel, lipid panel, A1c, and in some patients a thyroid panel. The specific panel depends on your clinical picture.

Is semaglutide right for everyone? No. Pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2, and certain GI conditions are contraindications or relative contraindications. A proper intake conversation surfaces these before therapy begins.

What if I can’t tolerate the nausea? Staying at a lower dose for an extra four weeks before escalating is the most common adjustment. Some clinicians also recommend smaller, more frequent meals and avoiding high-fat foods during the early weeks. If symptoms are severe and persistent, the prescribing clinician may pause the dose or adjust the plan.

Can I switch between compounded and brand-name semaglutide? In principle, yes, as long as the milligram dose is matched. In practice, confirm the exact dose and schedule with both the outgoing and incoming prescriber to avoid gaps or accidental dose changes.

References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).

Important Notice

Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.